Therapeutic Effect of Targeted Hyaluronan Binding Peptide on Neurofibromatosis
Abstract
To test our hypothesis that the HA binding peptide may be a new anti-neurofibromatosis agent via inducing apoptosis, we have proposed to focus on three aims: 1) To examine the anti-tumor effect of synthetic HA binding peptide on malignant neurofibromatosis cells; 2) To examine the anti-tumor effect of genetically expressed targeted HA binding peptide; 3) To examine the effect of targeted HA binding peptide on molecules involved in apoptosis. The results of first year study indicated that: 1) large scale synthesized HA binding peptide did possess HA binding activity; 2) synthetic HA binding peptide exerted an anti-tumor effect of on ST88-14 NFl cells; 3) HA binding peptide could bind to Bcl-2/Bcl-x(L), which may be one of the mechanisms by which HA binding peptide inhibits ST88-14 NFl cells; and 4) the cells transfected with expression vector carrying cDNA of HABP could express this peptide. The results of this year study demonstrated that: 1) HA binding peptide is capable of reducing the level of phosphorylated ERK1; 2) HABP reduces the level of cell cycle related molecules, such as cyclin B1 and cdc 2; 3) HABP binds to Bcl-2 in vivo and induces apoptosis; and 4) the effort has been made to set up the model system of NFl tumor exnograft in mice for test the effect of HABP in vivo. In the next year, we will continue to examine the action mechanism of HABP and to test if the in vitro anti-tumor effect of HA binding peptide can be translated in vivo against the cell growth of neurofibromatosis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2003
- Accession Number
- ADA420850
Entities
People
- Lurong Zhang
Organizations
- Georgetown University